- Home
- MRM vs ATHA Comparison
MRM vs ATHA Comparison
Compare MRM & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | ATHA |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 18.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRM | ATHA |
|---|---|---|
| Price | $2.07 | $7.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 90.2K | ★ 3.1M |
| Earning Date | 05-22-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $55,915,220.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.02 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $0.34 | $2.20 |
| 52 Week High | $4.45 | $8.36 |
Technical Indicators
Market Signals| Indicator | MRM | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 81.18 |
| Support Level | $2.10 | $7.03 |
| Resistance Level | $2.28 | $7.65 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | -0.00 | 0.34 |
| Stochastic Oscillator | 16.72 | 80.68 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.